NCT07910812Recruiting
Impact of a Tailored Digital Intervention on Sedentary Behaviour and Physical Health in Long-term Cardiac Rehabilitation Patients
Effects of a Tailored Intervention With Digital Health Tools on Sedentary Behaviour and Health-related Physical Outcomes in Long-term Cardiac Rehabilitation Patients: a Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
Sedentary behaviour (SB) is an independent cardiovascular risk factor that remains highly prevalent among individuals attending long-term cardiac rehabilitation (CR) programs, despite participation in regular supervised exercise. Although CR provides an ideal setting for promoting healthy lifestyle behaviours, evidence on tailored interventions specifically targeting SB in long-term CR programs remains limited. This randomized controlled trial aims to evaluate the effectiveness of a 6-month tailored behavioural intervention, supported by digital health tools, in reducing SB among adults attending a long-term phase CR program. Participants will be randomly allocated to either an intervention group (IG), receiving standard CR plus individualized behavioural counselling, digital prompts, and educational resources, or a standard care group (SCG) receiving usual CR and educational resources only. The primary outcome is objectively measured daily sedentary time assessed using activPAL4 (h/day). Secondary outcomes include objectively measured physical activity (PA), body composition, cardiorespiratory fitness, muscular strength, health-related quality of life and other behavioural outcomes. Outcomes will be assessed at baseline, 3, 6, and 12 months, according to the specific assessment schedule. The study aims to determine whether integrating a tailored behavioural intervention into routine long-term CR leads to sustained improvements in SB and related health outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- First submitted
- 7 Jul 2026
- Start date
- 1 Oct 2025
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- University of Lisbon
- Diseases
- Heart failure, Coronary artery disease
- NCT number
- NCT07910812
What you commit to
- Study type: Interventional
- Planned participants: 64
- From 1 Oct 2025 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Unable or unwilling to provide written informed consent
- Do not own a smartphone compatible with the study digital health tools
Who the study is looking for
- Adults aged 18 years or older
- Clinically stable
- Documented cardiovascular disease (CVD), including angiographically documented coronary artery disease involving at least one major epicardial vessel, previous myocardial infarction, previous coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting), heart failure (including cardiac transplantation), heart valve surgery or prosthetic valve/clip implantation, left ventricular assist devices, cardiac resynchronization therapy devices, implantable cardioverter-defibrillators, pacemakers, or congenital heart disease
- Enrolled in a long-term (phase III) cardiac rehabilitation (CR) programme for at least 6 months
- More than 8 hours per day of sedentary behaviour (SB), objectively assessed using activPAL4 during the baseline assessment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine of the University of Lisbon Coordinator of this site? Confirm its status | Lisbon | Portugal | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.